Are you or a loved one considering gene therapy as a treatment option for transfusion dependent beta thalassemia? Watch the recording of the Gene Therapy Webinar featuring Dr. Sujit Sheth and reps from bluebird bio now!
Are you or a loved one considering gene therapy as a treatment option for transfusion dependent beta thalassemia? Watch the recording of the Gene Therapy Webinar featuring Dr. Sujit Sheth and reps from bluebird bio now!
bluebird bio, Inc. announced the FDA has approved ZYNTEGLO®, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell transfusions.
Researchers from Weill Cornell Medical College may have discovered the precise role of a gene in beta-thalassemia, The study, entitled “Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in B-thalassemia” was published in the May 14, 2008 online issue of the journal Blood, the official publication of the American Society of Hematology (ASH). Splenectomy (spleen removal) […]
